AstraZeneca Secures CDSCO Approval for Expanded Use of Imfinzi in Endometrial Cancer Treatment
AstraZeneca Pharma India Ltd announced on Tuesday (February 10, 2026) that it has obtained approval from India’s drug regulator to market its cancer therapy, Durvalumab (brand name Imfinzi), for an additional indication. In a regulatory filing, the company stated that the Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, has granted permission to import, sell, and distribute Durvalumab solution for infusion in strengths of 120 mg/2.4 ml and 500 mg/10 ml for expanded therapeutic use. With this latest approval, Durvalumab can now be used in combination with chemotherapy drugs carboplatin and paclitaxel as a first-line treatment for adults diagnosed with primary advanced or recurrent endometrial cancer who are eligible for systemic therapy. Following combination treatment, the drug is also approved as a standalone maintenance therapy for patients with mismatch repair deficient (dMMR) endometrial cancer. The company noted that this regulatory clearance enables the commercial rollout of Imfinzi for the newly approved indication in India, subject to completion of other necessary statutory formalities. Source: PTI
